Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 688 results
Found 688 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

R

Swindells S, A DiRienzo G, Wilkin T, et al. "Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression." JAMA. 2006;296(7):806-14.
Wilkin TJ, McKinnon JE, A DiRienzo G, et al. "Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes." J. Infect. Dis.. 2009;199(6):866-71.
Tashima KT, Mollan KR, Na L, et al. "Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity." HIV Clin Trials. 2015;16(4):147-56.
Longenecker CT, Kitch D, Sax PE, et al. "Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s." J. Acquir. Immune Defic. Syndr.. 2015;69(2):168-77.
Kendall MA, Andersen JW, van der Horst C. "A reduced frequency visit schedule underreports adverse events that resulted in dose modifications or treatment discontinuations in HIV/AIDS clinical trials: ACTG DACS 207." Contemp Clin Trials. 2006;27(3):287-94.
Bednasz CJ, Sawyer JR, Martinez A, et al. "Recent advances in management of the HIV/HCV coinfected patient." Future Virol. 2015;10(8):981-997.
Wilkin TJ, Goetz MBidwell, Leduc R, et al. "Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity." Clin. Infect. Dis.. 2011;52(7):925-8.
Timmermans EC, Tebas P, Ruiter JPN, Wanders RJA, de Ronde A, de Baar MP. "Real-time nucleic acid sequence-based amplification assay to quantify changes in mitochondrial DNA concentrations in cell cultures and blood cells from HIV-infected patients receiving antiviral therapy." Clin. Chem.. 2006;52(6):979-87.
Shafer RW. "Rationale and uses of a public HIV drug-resistance database." J. Infect. Dis.. 2006;194 Suppl 1:S51-8.
Benson CA, Vaida F, Havlir DV, et al. "A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086." J. Infect. Dis.. 2006;194(9):1309-18.
Demeter LM, Jiang H, A Mukherjee L, et al. "A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients." AIDS. 2009;23(3):357-68.
Currier JS, Britto P, Hoffman RM, et al. "Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 ≥ 400 cells/mm3." PLoS ONE. 2017;12(5):e0176009.
Bosch RJ, Pollard RB, Landay A, Aga E, Fox L, Mitsuyasu R. "A randomized trial of interleukin-2 during withdrawal of antiretroviral treatment." J. Interferon Cytokine Res.. 2011;31(6):481-3.
Evans SR, Simpson DM, Kitch DW, et al. "A randomized trial evaluating Prosaptide for HIV-associated sensory neuropathies: use of an electronic diary to record neuropathic pain." PLoS ONE. 2007;2(6):e551.
Gandhi RT, O'Neill D, Bosch RJ, et al. "A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy." Vaccine. 2009;27(43):6088-94.
Collier AC, Tierney C, Downey GF, et al. "Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV." HIV Clin Trials. 2008;9(2):91-102.
Riddler SA, Jiang H, Tenorio A, et al. "A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115." Antivir. Ther. (Lond.). 2007;12(4):531-41.
Hammer SM, Ribaudo H, Bassett R, et al. "A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen." HIV Clin Trials. 2010;11(6):312-24.
O'Brien MP, Hunt PW, Kitch DW, et al. "A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy." Open Forum Infect Dis. 2017;4(1):ofw278.
J Kilby M, R Bucy P, Mildvan D, et al. "A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024)." J. Infect. Dis.. 2006;194(12):1672-6.
Fischl MA, Collier AC, A Mukherjee L, et al. "Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen." AIDS. 2007;21(3):325-33.
Jacobson JM, Wang H, Bordi R, et al. "A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2014;66(4):399-406.
Peters MG, Andersen J, Lynch P, et al. "Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127." Hepatology. 2006;44(5):1110-6.
Erlandson KM, Taejaroenkul S, Smeaton L, et al. "A Randomized Comparison of Anthropomorphic Changes With Preferred and Alternative Efavirenz-Based Antiretroviral Regimens in Diverse Multinational Settings." Open Forum Infect Dis. 2015;2(3):ofv095.
Albrecht M, A Mukherjee L, Tierney C, et al. "A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study." HIV Clin Trials. 2011;12(4):201-14.
Court R, Gordon M, Cohen K, et al. "Random lopinavir concentrations predict resistance on lopinavir-based antiretroviral therapy." Int. J. Antimicrob. Agents. 2016;48(2):158-62.
La Rosa AM, Harrison LJ, Taiwo B, et al. "Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study." Lancet HIV. 2016;3(6):e247-58.
Simoni JM, Huh D, Wilson IB, et al. "Racial/Ethnic disparities in ART adherence in the United States: findings from the MACH14 study." J. Acquir. Immune Defic. Syndr.. 2012;60(5):466-72.
Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM. "Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095." J. Acquir. Immune Defic. Syndr.. 2007;46(5):547-54.
Ribaudo HJ, Smith KY, Robbins GK, et al. "Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis." Clin. Infect. Dis.. 2013;57(11):1607-17.

Pages